传明酸的全球市场 (～2035年):製剂类型·用途·通路·终端用户·剂型·各地区

全球氨甲环酸市场规模预计将从 2024 年的 10.3747 亿美元增至 2035 年的 18.6199 亿美元，预测期内的复合年增长率为 5.38%。

全球氨甲环酸市场正在迅速扩张，主要受医疗、製药和化妆品领域对有效止血剂的需求不断增长的推动。氨甲环酸越来越多地被用于预防手术、创伤和月经失调引起的过度出血，并在医院、诊所、家庭保健和紧急护理环境中得到越来越广泛的应用。此外，由于人们广泛认识到氨甲环酸在皮肤病学和化妆品应用方面的益处，特别是在治疗色素沉着方面，市场正在扩大。

此外，药物製剂技术和输送机制的技术创新提高了生物利用度和治疗效果，大大改变了市场环境。氨甲环酸的创新配方，如脂质体和奈米颗粒配方，有助于提高治疗效果，同时减少副作用。此外，与其他活性成分的联合疗法的开发扩大了氨甲环酸在医疗和美容应用中的适应症范围，进一步推动了市场成长。

区域分析

在全球氨甲环酸市场中，北美是主导地区，这得益于其先进的医疗保健基础设施、较高的手术量以及对出血控制的认识不断提高。由于创伤相关损伤数量的增加、支持性监管政策以及外科治疗的扩大，美国和加拿大在氨甲环酸应用方面一直处于领先地位。

欧洲是一个成熟且监管良好的地区，其特点是广泛的临床可及性、强有力的政府支持和成熟的製药製造能力。欧洲药品管理局 (EMA) 和国家监管机构已批准氨甲环酸用于多种医疗用途，确保其在医疗机构中的标准化使用。亚太地区正在经历快速增长，推动力包括药品生产规模扩大、创伤性损伤发生率高、对妇幼健康的日益关注以及外科手术数量的增加。

本报告提供全球传明酸的市场调查，彙整市场定义和概要，市场成长的各种影响因素分析，市场规模的转变·预测，各种区分·地区/各主要国家的明细，竞争环境，主要企业简介等资讯。

目录

第1章 摘要整理

第2章 市场概要

第3章 调查手法

第4章 市场动态

• 成长参数地图:促进要素
  • 增加外科手术
  • 创伤病例增加
  • 月经过多的发生率增加
• 分配
  • 严格的监理要求
  • 新配方研发成本高昂
• 市场机会图
  • 对微创和非手术治疗方案的需求不断增加
  • 新兴市场尚未开发的潜力

第5章 市场要素分析

• 波特的五力分析
• COVID-19影响分析

第6章 全球传明酸市场:製剂各类型

• 口服剂
• 注射剂
• 局部剂

第7章 全球传明酸市场:各用途

• 月经过多
• 外科的出血控制
• 外伤·伤
• 遗传性血管水肿(HAE)
• 产后出血
• 其他

第8章 全球传明酸市场:各终端用户

• 医院·诊所
• 门诊病人手术中心
• 其他

第9章 全球传明酸市场:各地区

• 概要
• 北美
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 其他
• 其他地区
  • 中东
  • 非洲
  • 南美

第10章 竞争情形

• 市场占有率分析
• 竞争仪表板
• 主要颠覆者与创新者
• 市场领导采用的策略
• 主要的展开与成长策略

第11章 企业简介

• PFIZER INC
• FRESENIUS KABI USA, LLC
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• MAXWELLIA LTD.
• AUROBINDO PHARMA USA
• SUN PHARMACEUTICAL INDUSTRIES LTD.
• APOTEX INC.
• FERRING PHARMACEUTICALS
• NORDIC PHARMA, INC
• EXELA PHARMA SCIENCES LLC

第12章 资料的引用

Global Tranexamic Acid Market Research Report By Formulation Type (Oral Tablets, Injectable Solutions, Topical Applications), By Application (Post-Surgical Bleeding, Menorrhagia, Trauma Cases, Dental Procedures), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Home Care Settings), By Dosage Form (Low Dosage, Standard Dosage, High Dosage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035

Market Overview

The Global Tranexamic Acid Market is anticipated to experience substantial growth during the review period, with a compound annual growth rate (CAGR) of 5.38%. It is anticipated that the market will attain a value of USD 1,861.99 million by the conclusion of the forecast period (2025-2035), with an estimated value of USD 1,037.47 million in 2024.

The global tranexamic acid market is expanding at a rapid pace, primarily due to the increasing demand for hemostatic agents that are effective in medical, pharmaceutical, and cosmetic applications. Tranexamic acid is being used more frequently to prevent excessive bleeding during surgeries, trauma cases, and menstrual disorders, which is promoting its widespread adoption in hospitals, clinics, home care, and emergency care settings. Furthermore, the market is expanding due to the increasing recognition of the advantages of tranexamic acid in dermatology and cosmetics, particularly for the treatment of hyperpigmentation.

The market landscape is being transformed by technological advancements in drug formulations and delivery mechanisms, which have enabled enhanced bioavailability and therapeutic efficacy. Innovative formulations of tranexamic acid, including liposomal and nanoparticle-based formulations, are improving treatment outcomes while diminishing adverse effects. Furthermore, the market is experiencing growth as a result of the expansion of the scope of tranexamic acid in medical and aesthetic applications through the development of combination therapies that incorporate other active ingredients.

Market Segmentation Analysis

In 2024, the oral segment held a market share of 47.67% based on Formulation Type and is anticipated to grow at a compound annual growth rate (CAGR) of 5.83% during the forecast period. This is primarily motivated by its broad accessibility, affordability, and convenience. The substantial market share of oral tablets is a result of their widespread prescription for conditions such as excessive menstrual bleeding and surgical bleeding prevention.

In 2024, the hospitals & clinics segment held a market share of 45.25% based on End User and is anticipated to grow at a compound annual growth rate (CAGR) of 5.23% during the forecast period. The high volume of surgical procedures, trauma cases, and critical care treatments that necessitate tranexamic acid for haemorrhage management is the reason for this growth.

Analysis of the Region

In the global tranexamic acid (TXA) market, North America is the dominant region due to its advanced healthcare infrastructure, high volume of surgical procedures, and growing awareness of blood loss management. The United States and Canada have been at the forefront of TXA adoption as a result of the increasing number of trauma-related injuries, supportive regulatory policies, and the expansion of surgical interventions.

Europe is a mature and well-regulated TXA market, characterized by pervasive clinical adoption, strong government support, and well-established pharmaceutical manufacturing capabilities. TXA has been certified for a variety of medical applications by the European Medicines Agency (EMA) and national regulatory bodies, thereby guaranteeing standardized usage across healthcare institutions. The Asia-Pacific (APAC) region is experiencing rapid expansion in the tranexamic acid (TXA) market, which is being driven by expanding pharmaceutical production, high trauma incidences, rising maternal healthcare concerns, and increasing surgical volumes. Countries such as Germany are among those in this region. The adoption of TXA is being led by countries such as China, India, Japan, South Korea, and Australia, which are benefiting from an increasing number of clinical applications, growing awareness about blood loss management, and rising healthcare investments.

Major Players

Pfizer Inc., Fresenius Kabi AG, Teva Pharmaceuticals, Maxwellia Ltd, Aurobindo Pharma, Sun Pharma, Apotex Inc, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Exela Pharma Sciences are among the notable participants in the industry.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW
• 1.2 MARKET ATTRACTIVENESS ANALYSIS
• 1.3 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE
• 1.4 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION
• 1.5 GLOBAL TRANEXAMIC ACID MARKET, BY END USER
• 1.6 GLOBAL TRANEXAMIC ACID MARKET, BY REGION

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research Data Flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research Data Flow:
  • 3.5.2 Primary Research: Number of Interviews conducted
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
• 3.7 DATA FORECASTING
  • 3.7.1 Data forecasting Type
• 3.8 DATA MODELING
  • 3.8.1 Microeconomic Factor Analysis:
  • 3.8.2 Data modeling:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 GROWTH PARAMETERS MAPPED - DRIVERS
  • 4.2.1 Increasing Surgical Procedures
  • 4.2.2 Growing Prevalence of Trauma Cases
  • 4.2.3 Growing Prevalence of Heavy Menstrual Bleeding (HMB)
• 4.3 WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS?
  • 4.3.1 Stringent Regulatory Requirements
  • 4.3.2 High R&D Costs for New Formulations
• 4.4 MARKET OPPORTUNITIES MAPPED
  • 4.4.1 Rising Demand for Minimally Invasive & Non-Surgical Treatment Options
  • 4.4.2 Untapped Potential in Emerging Markets

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 Bargaining Power of Suppliers
  • 5.1.2 Bargaining Power of Buyers
  • 5.1.3 Threat of New Entrants
  • 5.1.4 Threat of Substitutes
  • 5.1.5 Intensity of Rivalry
• 5.2 COVID-19 IMPACT ANALYSIS
  • 5.2.1 Impact on R & D
  • 5.2.2 Impact on Supply Chain
  • 5.2.3 Impact on Pricing

6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE

• 6.1 INTRODUCTION
• 6.2 ORAL
• 6.3 INJECTABLE
• 6.4 TROPICAL

7 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 MENORRHAGIA
• 7.3 SURGICAL BLEEDING CONTROL
• 7.4 TRAUMA AND INJURY
• 7.5 HEREDITARY ANGIOEDEMA (HAE)
• 7.6 POSTPARTUM HEMORRHAGE
• 7.7 OTHERS

8 GLOBAL TRANEXAMIC ACID MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS & CLINICS
• 8.3 AMBULATORY SURGICAL CENTERS
• 8.4 OTHERS

9 GLOBAL TRANEXAMIC ACID MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 UK
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024
• 10.3 COMPETITION DASHBOARD
  • 10.3.1 PRODUCT PORTFOLIO
  • 10.3.2 REGIONAL PRESENCE
  • 10.3.3 STRATEGIC ALLIANCES
  • 10.3.4 INDUSTRY EXPERIENCES
• 10.4 WHO ARE THE MAJOR DISRUPTORS & INNOVATORS
• 10.5 WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 Merger and Acquisition
  • 10.6.2 Product launch

11 COMPANY PROFILES

• 11.1 PFIZER INC
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 Key Strategy
• 11.2 FRESENIUS KABI USA, LLC
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 Key Strategy
• 11.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 Key Strategy
• 11.4 MAXWELLIA LTD.
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 PRODUCTS OFFERED
  • 11.4.3 KEY DEVELOPMENTS
  • 11.4.4 SWOT ANALYSIS
  • 11.4.5 Key Strategy
• 11.5 AUROBINDO PHARMA USA
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 PRODUCTS OFFERED
  • 11.5.3 KEY DEVELOPMENTS
  • 11.5.4 SWOT ANALYSIS
  • 11.5.5 Key Strategy
• 11.6 SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 Key Strategy
• 11.7 APOTEX INC.
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 PRODUCTS OFFERED
  • 11.7.3 KEY DEVELOPMENTS
  • 11.7.4 SWOT ANALYSIS
  • 11.7.5 Key Strategy
• 11.8 FERRING PHARMACEUTICALS
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 PRODUCTS OFFERED
  • 11.8.3 KEY DEVELOPMENTS
  • 11.8.4 SWOT ANALYSIS
  • 11.8.5 Key Strategy
• 11.9 NORDIC PHARMA, INC
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 PRODUCTS OFFERED
  • 11.9.3 KEY DEVELOPMENTS
  • 11.9.4 SWOT ANALYSIS
  • 11.9.5 Key Strategy
• 11.10 EXELA PHARMA SCIENCES LLC
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 PRODUCTS OFFERED
  • 11.10.3 KEY DEVELOPMENTS
  • 11.10.4 SWOT ANALYSIS
  • 11.10.5 Key Strategy

12 DATA CITATIONS

LIST OF TABLES

• TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
• TABLE 2 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 3 GLOBAL TRANEXAMIC ACID MARKET, FOR ORAL, BY REGION, 2019-2035 (USD MILLION)
• TABLE 4 GLOBAL TRANEXAMIC ACID MARKET, FOR INJECTABLE, BY REGION, 2019-2035 (USD MILLION)
• TABLE 5 GLOBAL TRANEXAMIC ACID MARKET, FOR TROPICAL, BY REGION, 2019-2035 (USD MILLION)
• TABLE 6 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 7 GLOBAL TRANEXAMIC ACID MARKET, FOR MENORRHAGIA, BY REGION, 2019-2035 (USD MILLION)
• TABLE 8 GLOBAL TRANEXAMIC ACID MARKET, FOR SURGICAL BLEEDING CONTROL, BY REGION, 2019-2035 (USD MILLION)
• TABLE 9 GLOBAL TRANEXAMIC ACID MARKET, FOR TRAUMA AND INJURY, BY REGION, 2019-2035 (USD MILLION)
• TABLE 10 GLOBAL TRANEXAMIC ACID MARKET, FOR HEREDITARY ANGIOEDEMA (HAE), BY REGION, 2019-2035 (USD MILLION)
• TABLE 11 GLOBAL TRANEXAMIC ACID MARKET, FOR POSTPARTUM HEMORRHAGE, BY REGION, 2019-2035 (USD MILLION)
• TABLE 12 GLOBAL TRANEXAMIC ACID MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 13 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 14 GLOBAL TRANEXAMIC ACID MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 15 GLOBAL TRANEXAMIC ACID MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 16 GLOBAL TRANEXAMIC ACID MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 17 GLOBAL TRANEXAMIC ACID MARKET, BY REGION, 2019-2035 (USD MILLION)
• TABLE 18 NORTH AMERICA TRANEXAMIC ACIDS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 19 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 20 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 21 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 22 US: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 23 US: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 24 US: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 25 CANADA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 26 CANADA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 27 CANADA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 28 EUROPE: TRANEXAMIC ACIDS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 29 EUROPE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 30 EUROPE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 31 EUROPE: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 32 GERMANY: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 33 GERMANY: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 34 GERMANY: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 35 UK: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 36 UK: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 37 UK: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 38 FRANCE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 39 FRANCE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 40 FRANCE: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 41 ITALY: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 42 ITALY: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 43 ITALY: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 44 SPAIN: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 45 SPAIN: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 46 SPAIN: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 47 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 48 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 49 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 50 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 51 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 52 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 53 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 54 CHINA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 55 CHINA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 56 CHINA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 57 INDIA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 58 INDIA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 59 INDIA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 60 JAPAN: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 61 JAPAN: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 62 JAPAN: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 63 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 64 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 65 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 66 AUSTRALIA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 67 AUSTRALIA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 68 AUSTRALIA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 69 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 70 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 71 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 72 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 73 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 74 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 75 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 76 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 77 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 78 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 79 AFRICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 80 AFRICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 81 AFRICA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 82 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 83 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 84 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 85 MERGER AND ACQUISITION
• TABLE 86 PRODUCT LAUNCH
• TABLE 87 PFIZER INC: PRODUCTS OFFERED
• TABLE 88 FRESENIUS KABI USA, LLC: PRODUCTS OFFERED
• TABLE 89 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED
• TABLE 90 MAXWELLIA LTD.: PRODUCTS OFFERED
• TABLE 91 AUROBINDO PHARMA USA: PRODUCTS OFFERED
• TABLE 92 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
• TABLE 93 APOTEX INC.: PRODUCTS OFFERED
• TABLE 94 FERRING PHARMACEUTICALS: PRODUCTS OFFERED
• TABLE 95 NORDIC PHARMA, INC: PRODUCTS OFFERED
• TABLE 96 EXELA PHARMA SCIENCES LLC: PRODUCTS OFFERED

LIST OF FIGURES

• FIGURE 1 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL TRANEXAMIC ACID MARKET, 2024
• FIGURE 2 GLOBAL TRANEXAMIC ACID MARKET ANALYSIS, BY FORMULATION TYPE, 2024
• FIGURE 3 GLOBAL TRANEXAMIC ACID ANALYSIS, BY APPLICATION, 2024
• FIGURE 4 GLOBAL TRANEXAMIC ACID ANALYSIS, BY END USER, 2024
• FIGURE 5 GLOBAL TRANEXAMIC ACID MARKET ANALYSIS, BY REGION, 2024
• FIGURE 1 GLOBAL TRANEXAMIC ACID MARKET: STRUCTURE
• FIGURE 2 GLOBAL TRANEXAMIC ACID MARKET: MARKET GROWTH FACTOR ANALYSIS (2019-2035)
• FIGURE 3 DRIVER IMPACT ANALYSIS (2019-2035)
• FIGURE 4 PORTER'S FIVE FORCES MODEL: GLOBAL TRANEXAMIC ACID MARKET
• FIGURE 5 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2024 & 2035 (USD MILLION)
• FIGURE 7 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY FORMULATION TYPE, 2024
• FIGURE 8 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 9 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION)
• FIGURE 10 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY APPLICATION, 2024
• FIGURE 11 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 12 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, 2024 & 2035 (USD MILLION)
• FIGURE 13 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY END USER, 2024
• FIGURE 14 GLOBAL TRANEXAMIC ACID MARKET, BY REGION, 2024 & 2035 (USD MILLION)
• FIGURE 15 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY REGION, 2024
• FIGURE 16 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 17 NORTH AMERICA: TRANEXAMIC ACID MARKET SHARE (%), BY COUNTRY, 2024
• FIGURE 18 EUROPE: TRANEXAMIC ACIDS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 19 EUROPE: TRANEXAMIC ACIDS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 20 ASIA-PACIFIC: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 21 ASIA-PACIFIC: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 22 REST OF THE WORLD: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 23 REST OF THE WORLD: TRANEXAMIC ACID MARKET SHARE, BY REGION, 2024 (%)
• FIGURE 24 GLOBAL TRANEXAMIC ACID MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
• FIGURE 25 COMPETITOR DASHBOARD: GLOBAL TRANEXAMIC ACID MARKET
• FIGURE 26 PFIZER INC: SWOT ANALYSIS
• FIGURE 27 FRESENIUS KABI USA, LLC: SWOT ANALYSIS
• FIGURE 28 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
• FIGURE 29 MAXWELLIA LTD: SWOT ANALYSIS
• FIGURE 30 AUROBINDO PHARMA USA: SWOT ANALYSIS
• FIGURE 31 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
• FIGURE 32 APOTEX INC.: SWOT ANALYSIS
• FIGURE 33 FERRING PHARMACEUTICALS: SWOT ANALYSIS
• FIGURE 34 NORDIC PHARMA, INC: SWOT ANALYSIS
• FIGURE 35 EXELA PHARMA SCIENCES LLC: SWOT ANALYSIS